O. Voitko

发表

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

N. Reinmuth, Y. Shrestha, Haiyi Jiang, 2019, Annals of Oncology.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

N. Reinmuth, N. Shire, Haiyi Jiang, 2019, Journal of Thoracic Oncology.

a of Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN):

N. Reinmuth, N. Shire, Haiyi Jiang, 2020 .

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

N. Reinmuth, Yuh-Min Chen, L. Paz-Ares, 2021, Annals of Oncology.

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, Journal of Clinical Oncology.

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

N. Reinmuth, N. Shire, Haiyi Jiang, 2020, Lung cancer.

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, The Lancet. Oncology.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

N. Reinmuth, Y. Shrestha, Yuh-Min Chen, 2020 .

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.

N. Byrne, L. Paz-Ares, J. Goldman, 2020 .